Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study. Issue 12 (22nd October 2019)

• Record Type: Journal Article
• Authors: Yokota, Kenji; Uchi, Hiroshi; Uhara, Hisashi; Yoshikawa, Shusuke; Takenouchi, Tatsuya; Inozume, Takashi; Ozawa, Kentaro; Ihn, Hironobu; Fujisawa, Yasuhiro; Qureshi, Anila; de Pril, Veerle; Otsuka, Yasushi; Weber, Jeffrey; Yamazaki, Naoya
• Is Part Of: Journal of dermatology. Volume 46:Issue 12(2019)
• Page Start: 1197
• Page End: 1201
• Publication Date: 2019-10-22
• Subjects: adjuvant drug therapy -- ipilimumab -- Japanese patients -- melanoma -- nivolumab; Dermatology -- Periodicals; Dermatology -- Japan -- Periodicals; Skin -- Diseases -- Periodicals; 616.5005
• DOI: 10.1111/1346-8138.15103
• Languages: English
• ISSNs: 0385-2407

Abstract

Abstract: The multinational phase 3 CheckMate 238 trial compared adjuvant therapy with nivolumab versus ipilimumab among patients with resected stage III or IV melanoma ( N = 906). In this Japanese subgroup analysis of CheckMate 238 ( n = 28; nivolumab, n = 18; ipilimumab, n = 10), both the 12‐ and 18‐month recurrence‐free survival rates were 56% for nivolumab and 30% for ipilimumab (hazard ratio, 0.66; 97.56% confidence interval, 0.19–2.24; P = 0.4390). No new safety signals were reported for Japanese patients. Results were consistent with those from the CheckMate 238 global population, indicating that nivolumab has the potential to be a treatment option for Japanese patients with resected melanoma who are at high risk of recurrence.